Silence Therapeutics plc (SLNCF)

Name: Silence Therapeutics plc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-03-31

Latest Quarter

2025-03-31

Revenue

$142K

Net Income

-$28.5M

Operating Margin

-20,006.3%

Free Cash Flow

-$62.3M

Debt / Assets

39.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Silence Therapeutics plc (SLNCF).
Income Statement (Quarterly)	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Revenue	142,000	24,327,760	1,142,000	598,000
Cost of Revenue	54,000	1,606,191	2,774,000	2,638,000
Gross Profit	88,000	22,721,569	-1,632,000	-2,040,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	7,684,000	5,395,113	5,600,000	5,288,000
Operating Expenses	28,497,000	25,799,959	20,905,000	16,283,000
Operating Income	-28,409,000	-3,078,391	-22,537,000	-18,323,000
Interest Expense	0	-11,544,689	8,602,000	183,000
Income Before Tax	-28,530,000	23,736,248	-30,158,000	-17,441,000
Income Tax Expense	0	9,562,063	-3,146,000	-1,879,000
Net Income	-28,530,000	14,174,185	-27,012,000	-15,562,000
Per Share
EPS	-0.60	0.31	-0.57	-0.33
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Silence Therapeutics plc (SLNCF).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	559,000	43,258,000	25,375,000	17,501,000
Cost of Revenue	215,000	11,810,000	10,318,000	10,880,000
Gross Profit	344,000	31,448,000	15,057,000	6,621,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	22,344,000	26,884,000	20,636,000	19,609,000
Operating Expenses	90,097,000	94,767,000	64,661,000	55,214,000
Operating Income	-61,215,064	-63,319,000	-49,604,000	-48,593,000
Interest Expense	0	0	34,000	47,000
Income Before Tax	-88,601,000	-44,464,000	-50,310,000	-47,368,000
Income Tax Expense	11,000	845,000	-7,043,000	-6,879,000
Net Income	-88,612,000	-45,309,000	-43,267,000	-40,489,000
Per Share
EPS	-1.89	-0.98	-1.17	-0.42
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Silence Therapeutics plc (SLNCF).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	11,277,000	121,330,000	54,031,000	54,816,000
Short Term Investments	73,837,000	26,004,000	0	16,328,000
Net Receivables	18,267,526	26,908,000	18,833,000	17,342,000
Inventory	0	0	0	-1,717,080
Total Current Assets	118,658,000	187,366,000	81,021,000	96,686,000
Property Plant Equipment	1,748,000	1,975,000	1,813,000	2,201,000
Goodwill and Intangibles	10,909,000	9,704,000	8,124,000	8,329,000
Total Assets	131,442,000	202,635,000	93,822,000	107,500,000
Liabilities
Account Payables	3,272,183	3,697,000	2,629,000	3,186,000
Short Term Debt	-89,000	117,000	179,000	446,000
Total Current Liabilities	10,103,023	16,822,000	17,769,000	21,943,000
Long Term Debt	-71,000	0	93,000	0
Total Liabilities	51,311,458	68,612,000	76,772,000	85,428,000
Shareholders Equity
Retained Earnings	-417,518,434	-474,044,000	-304,612,000	-263,263,000
Total Shareholders Equity	46,239,536	134,023,000	17,050,000	22,072,000

Balance sheet annual history for Silence Therapeutics plc (SLNCF).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	11,277,000	121,330,000	54,031,000	54,816,000
Short Term Investments	73,837,000	26,004,000	0	16,328,000
Net Receivables	18,267,526	26,908,000	18,833,000	17,342,000
Inventory	0	0	0	-1,717,080
Total Current Assets	118,658,000	187,366,000	81,021,000	96,686,000
Property Plant Equipment	1,748,000	1,975,000	1,813,000	2,201,000
Goodwill and Intangibles	10,909,000	9,704,000	8,124,000	8,329,000
Total Assets	131,442,000	202,635,000	93,822,000	107,500,000
Liabilities
Account Payables	3,272,183	3,697,000	2,629,000	3,186,000
Short Term Debt	-89,000	117,000	179,000	446,000
Total Current Liabilities	10,103,023	16,822,000	17,769,000	21,943,000
Long Term Debt	-71,000	0	93,000	0
Total Liabilities	51,311,458	68,612,000	76,772,000	85,428,000
Shareholders Equity
Retained Earnings	-417,518,434	-474,044,000	-304,612,000	-263,263,000
Total Shareholders Equity	46,239,536	134,023,000	17,050,000	22,072,000

Cash flow quarterly history for Silence Therapeutics plc (SLNCF).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-88,612,000	-36,190,110	-50,310,000	-47,368,000
Depreciation & Amortization	312,000	593,000	498,000	482,000
Stock Based Compensation	8,074,000	13,025,053	13,050,000	10,252,000
Change in Working Capital	7,557,222	-33,023,000	-11,662,000	-8,263,000
Operating Cash Flow	-62,271,000	-67,640,000	-39,350,000	-45,456,000
Investing Activities
Capital Expenditure	-55,000	-211,000	-45,000	-440,000
Investments	-55,000	-211,000	-45,000	-440,000
Investing Cash Flow	-35,700,976	-21,966,000	16,430,000	-16,542,000
Financing Activities
Debt Repayment	0	0	-174,000	-190,000
Common Stock Issued/Repurchased	11,158	142,087,000	25,329,000	43,239,000
Dividends Paid	0	0	0	0
Financing Cash Flow	11,158	142,087,000	25,155,000	43,049,000
Summary
Free Cash Flow	-62,326,000	-67,851,000	-39,395,000	-45,896,000
Net Change in Cash	-81,676,934	52,541,000	-785,000	-18,721,000

Cash flow annual history for Silence Therapeutics plc (SLNCF).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-88,612,000	-36,190,110	-50,310,000	-47,368,000
Depreciation & Amortization	312,000	593,000	498,000	482,000
Stock Based Compensation	8,074,000	13,025,053	13,050,000	10,252,000
Change in Working Capital	7,557,222	-33,023,000	-11,662,000	-8,263,000
Operating Cash Flow	-62,271,000	-67,640,000	-39,350,000	-45,456,000
Investing Activities
Capital Expenditure	-55,000	-211,000	-45,000	-440,000
Investments	-55,000	-211,000	-45,000	-440,000
Investing Cash Flow	-35,700,976	-21,966,000	16,430,000	-16,542,000
Financing Activities
Debt Repayment	0	0	-174,000	-190,000
Common Stock Issued/Repurchased	11,158	142,087,000	25,329,000	43,239,000
Dividends Paid	0	0	0	0
Financing Cash Flow	11,158	142,087,000	25,155,000	43,049,000
Summary
Free Cash Flow	-62,326,000	-67,851,000	-39,395,000	-45,896,000
Net Change in Cash	-81,676,934	52,541,000	-785,000	-18,721,000